- Report
- March 2018
- 95 Pages
Global
From €4230EUR$4,450USD£3,554GBP
- Report
- August 2023
- 145 Pages
Global
From €2995EUR$3,150USD£2,516GBP
- Report
- November 2021
- 82 Pages
Middle East, Africa
From €1426EUR$1,500USD£1,198GBP
- Report
- October 2023
- 146 Pages
Global
From €3353EUR$3,528USD£2,817GBP
€3945EUR$4,150USD£3,314GBP
- Report
- October 2023
- 428 Pages
Global
From €3394EUR$3,570USD£2,851GBP
The Presymptomatic Testing market within the context of Genomics is a rapidly growing sector of the healthcare industry. It involves the use of genetic testing to identify individuals who are at risk of developing a particular disease before any symptoms appear. This type of testing can be used to identify genetic mutations that may lead to the development of a disease, allowing for early intervention and prevention. It can also be used to identify individuals who are at risk of passing on a genetic disorder to their children.
Presymptomatic testing is becoming increasingly popular as it allows for early detection and treatment of diseases, which can improve patient outcomes and reduce healthcare costs. It is also being used to identify individuals who may be at risk of developing certain types of cancer.
Companies in the Presymptomatic Testing market include 23andMe, Color Genomics, Invitae, Counsyl, and Myriad Genetics. Show Less Read more
